The treatment of triple-negative breast cancer (TNBC) is particularly challenging, due to its negligible expression of targetable receptors like estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/Neu/ErbB2) [11,12]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.